www.demosthenes.nl

[Adrie & Miep]

[Topic gesplitst door de beheerder op verzoek van Adrie]

[ET]

New drug to treat stuttering


http://nl.truveo.com/New-drug-to-treat-stuttering/id/427794374
_________________
Stichting Encouraging-Training Schoenaker-concept®

[ET]

Stuttertalk.com

Dr. Gerald Maguire over de huidige stand van zaken rond het onderzoek naar Pagoclone en medische behandeling van stotteren bij kinderen en jeugdigen. http://stuttertalk.com/2009/05/12/gerald-maguire-pagoclone-stuttering.aspx
_________________
Stichting Encouraging-Training Schoenaker-concept®

[ET]

Pagoclone trial finished?



Maart j.l begon in de USA een studie naar de effecten van behandeling van stotteren met het geneesmiddel Pagoclone.

Ook zo benieuwd de resultaten?
Lees hier de ervaring van een deelnemer aan het Pagoclone onderzoek
_________________
Stichting Encouraging-Training Schoenaker-concept®

[ET]

"I`m going in the open label phase in december, I also will keep you updated, but just to let you know, there are people that have gotten great results from what I was told. I have noticed zero for speech enhancement and side effects, there is a big chance I am on the placebo, I will know in december when they give me the real meds." 21.10.2009

"Hi everybody, I have been involved in the clinical trail on Pacoclone for more that 6 months. Right now, I am on the last batch of the double-blinded phase. The first three batches of the pills which I took, had little or no effect on my speech. However, this last batch really have a positive effect on my speech. It seems like a miracle." 21.10.2009

Info: A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering
_________________
Stichting Encouraging-Training Schoenaker-concept®

[ET]

Pagoclone brings hope for stutterers



www.youtube.com/watch?v=Bslyadg5MRo

Pagoclone could become the first FDA-approved drug for stuttering. The drug was being studied for premature ejaculation when researchers noticed an interesting side effect - patients with a stuttered had clearer speech.
Pagoclone affects levels of 2 brain chemicals - dopamine and GABA - which are believed to play a role in stuttering.

Pagoclone: a possible medical treatment for stuttering



http://www.youtube.com/watch?v=N4oWey2U03Q


For the first time ever there might be a medical treatment for stuttering. At least three million americans stutter. It can be a problem that affects self esteem and almost every other aspect of a person's life. Doctors always thought that stuttering was caused by stress and the problem area was in the vocal cords. But now doctors think stuttering may actually be caused by a defect in the brain and now there's a medication that appears to a solution for some.

Pagoclone is anxiolytic drug van cyclopyrrolone familie, die ....Lees verder
_________________
Stichting Encouraging-Training Schoenaker-concept®

[Mario]

Mocht het medicijn in Nederland en België komen, wie zou zich kandidaat stellen om het uit te proberen ???
_________________
Behandel anderen zoals jezelf behandeld wilt worden.

[Chris80]

Ik ben redelijk sceptisch tegenover geclaimde wondermiddeltjes, maar dit interesseert me wel degelijk. De filmpjes zijn kort maar het lijkt wetenschappelijk aardig onderlegd te zijn. Of dit voor mij een optie zou zijn hangt er vooral vanaf wat eventuele bijwerkingen zijn zouden zijn, de kosten en hoe ik me de kuur voor moet stellen. In ieder geval is wel iets dat ik als potentieel interessant zie!

[ET]

De eerste gedetailleerde publicatie van de resultaten van het onderzoek met Pagoclone [fase 2] is verschenen.

Exploratory Randomized Clinical Study of Pagoclone in Persistent Developmental Stuttering The EXamining Pagoclone for peRsistent dEvelopmental Stuttering Study

Zie: Journal of Clinical Psychopharmacology - Vol 30, Nr 1, febr 2010

Introduction: Stuttering is a speech disorder in which the flow of speech is disrupted by repetitions, prolongation, and blocks of sounds, syllables, or words. No pharmacological treatments are approved for use in stuttering, and the most common form of treatment is speech therapy. This study was designed to assess the safety, tolerability, and effectiveness of pagoclone during 8 weeks of double-blind treatment followed by a 1-year open-label extension in patients who stutter.
Methods: An 8-week, multicenter, parallel-group, 2-arm, randomized (ratio 2:1 pagoclone-placebo), double-blind study with a 1-year open-label extension conducted at 16 US centers, including men and women aged 18 to 65 years who developed stuttering before 8 years of age. Twice-daily dosing with pagoclone (n = 88 patients) or matching placebo (n = 44 patients), with primary and secondary efficacy variables defined a priori, including Stuttering Severity Instrument Version 3 outcomes, clinician global impressions of improvement, and the change in the percentage of syllables stuttered.
Results: Pagoclone produced an average 19.4% reduction in percentage of syllables stuttered compared with 5.1% reduction for placebo. During open-label treatment, a 40% reduction in the percent syllables stuttered was observed after 1 year of treatment with pagoclone. The most commonly reported adverse event during double-blind treatment was headache (12.5% pagoclone patients, 6.8% placebo patients).
Discussion: Pagoclone was effective in reducing symptoms of stuttering and was well tolerated. In light of its favorable tolerability profile, as well as consistency of effects across multiple efficacy variables, pagoclone may have potential as a pharmacological treatment of stuttering.
Limitations: The main limitation of this study was the adequacy of the number of subjects who participated because this study was conducted as a pilot investigation. Furthermore, as this condition waxes and wanes, the assessment of stuttering within the clinic setting may not be an adequate reflection of the stuttering of the patients within the community.


_________________
Stichting Encouraging-Training Schoenaker-concept®

[ET]

Ik zie zojuist op thestutteringbrain.blogspot.com een reactie van één van de deelnemers aan dit onderzoek - en lees daarin de opmerking van de arts over fase 2b. De arts acht de kans dat het middel wordt toegelaten meer dan 50% Klik hier>>
Dat maakt mij toch wat achterdochtig. Wordt er toegewerkt aan het op de markt brengen van dit middel?
Immers, dit onderzoek wordt betaald door de firma die ook het patent op Pagoclone bezit.
_________________
Stichting Encouraging-Training Schoenaker-concept®

[maurice]

[ET]

[ET]

"Ik stotter nog steeds, maar mijn blokkaden zijn minder intens en minder frequent..." Ervaringsbericht pagoclone>>>

Stuttering Study - Pagoclone Trials youtube >>>
Men and women who stutter often have so much to say, but may not always say it the way they want. As part of a new nationwide clinical study, the University of Utah School of Medicine Mood Disorders Clinic is enrolling participants to test whether an investigational medication for stuttering may offer a way to help those who stutter achieve more fluent speech. http://www.youtube.com/watch?v=ZiiqdD-kbc8

Pagoclone: a possible medical treatment for stuttering youtube>>>
For the first time ever there might be a medical treatment for stuttering. At least three million americans stutter. It can be a problem that affects self esteem and almost every other aspect of a person's life. Doctors always thought that stuttering was caused by stress and the problem area was in the vocal cords. But now doctors think stuttering may actually be caused by a defect in the brain and now there's a medication that appears to a solution for some. http://www.youtube.com/watch?v=N4oWey2U03Q


_________________
Stichting Encouraging-Training Schoenaker-concept®

[ET]

De publicatie van fase IIb van het Pagoclone-onderzoek laat om onduidelijke redenen op zich wachten.
Vallen de resultaten soms wat tegen?
Tom Weidig heeft daar zo zijn bedenkingen bij....:

Waiting for the Pagoclone study....
Posted Jun 24 2010 12:40am
The Pagoclone Phase IIb study has still not been published. Several sources tell me that the company TEVA has all the data for several weeks now. There is no doubt in my mind that they know the outcome of the study. Sometimes they wait with an announcement to coincide with another corporate event. But the longer we have to wait, the more pessimistic I get. Do they actually have to publish the study? What if the study turns out to be a null-result, do they have to publish the details? I believe that they have to register their study, but I am sure how much of the data they have to release. It's very important that all studies are made public. If only the positive ones are published but the null ones not, we have a publication bias. And that can be a big big issue. Bron

http://thestutteringbrain.blogspot.com/
_________________
Stichting Encouraging-Training Schoenaker-concept®

[ET]

BREAKING NEWS: PAGOCLONE NOT SUCCESSFUL
Het medicijn PAGOCLONE is niet effectief bij de behandeling van stotteren
Lees meer >>

Endo Pharmaceuticals heeft de eerste analyses van de gegevens van het lopend onderzoek voltooid.
Een paar aanvullende gegevenanalyses volgen nog voor het einde van dit jaar.
Deelnemers aan het onderzoek worden geadviseerd om andere behandelingsopties te bespreken met hun arts. Zie rapport >>>
Pagoclone is dus niet het wondermiddel waar velen op hebben gehoopt.



Bron
_________________
Stichting Encouraging-Training Schoenaker-concept®